We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
Read MoreHide Full Article
Illumina, Inc. (ILMN - Free Report) recently signed a partnership deal with Adaptive Biotechnologies Corporation (ADPT - Free Report) , a commercial stage biotechnology company. The deal will enable clinicians to carry out clinical immunodiagnostic testing that can be conducted in local laboratories. Moreover, the collaboration will boost Illumina’s strong in-vitro diagnostic (IVD) portfolio.
Adaptive Biotechnologies is striving to decode the genetics of the adaptive immune system into clinical products to diagnose and treat diseases.
Also, the collaboration will enable Illumina to improve its foothold in the global IVD market.
Significance of the Collaboration
Per the terms of the partnership, Illumina will develop customized software to support the use of the kits on NextSeq instruments. Also, the company will provide regulatory and related support related to its components as well as the software. It will exclusively license the software to Adaptive Biotechnologies. These test kits will enable hospitals and healthcare providers to use Adaptive Biotechnologies’ clonoSEQ and immunoSEQ Dx assays in their respective laboratories across the United States.
Through this collaboration, Illumina aims to reach out to more people to ensure better access to healthcare. Also, it plans to make clonoSEQ more accessible to patients and include the healthcare providers into the growing genomics ecosystem. The partnership will facilitate Illumina to expand access to genomic-based testing and improve patient outcomes.
A Peek Into Illumina’s IVD Portfolio
Illumina’s next-generation sequencing (NGS) technology offers broader view of the human genome. This helps clinicians to determine and apply relevant genomic information to human health. The company is focused on improving health by tapping the huge potential of the human genome.
Illumina is currently aiming to expand the clinical applications of its NGS platform through products like the MiSeqDx System and the TruSeq Custom Amplicon Kit Dx.
Recent Developments
The company announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to noninvasive prenatal testing (NIPT) in June 2019. It is an automated comprehensive solution that enables laboratories to look for a broader array of chromosomal and sub-chromosomal conditions associated with birth defects as well as adverse pregnancy outcomes than the standard NIPT menu.
Industry Prospects
Per a report by Research And Markets, the global IVD market value is anticipated to reach $92.54 billion at a CAGR of 6.6%, for the period spanning from 2018 to 2023. The key factors driving the market is the increasing numbers of diabetic patients, rising incidents of chronic ailments, surging healthcare expenditure and rising elderly population.
Given the current trend, Illumina signed this distribution deal just at the right time.
Price Performance
The company’s shares have plunged 18.3% in the past year compared with the industry’s decline of 27.5%. However, the S&P 500 index inched up 0.9% during the same period.
Zacks Rank & Key Picks
Currently, Illumina carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Capricor Therapeutics, Inc (CAPR - Free Report) and GW Pharmaceuticals PLC .
GW Pharmaceuticals estimates third-quarter earnings growth rate to be 72.8%. It currently flaunts a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
Illumina, Inc. (ILMN - Free Report) recently signed a partnership deal with Adaptive Biotechnologies Corporation (ADPT - Free Report) , a commercial stage biotechnology company. The deal will enable clinicians to carry out clinical immunodiagnostic testing that can be conducted in local laboratories. Moreover, the collaboration will boost Illumina’s strong in-vitro diagnostic (IVD) portfolio.
Adaptive Biotechnologies is striving to decode the genetics of the adaptive immune system into clinical products to diagnose and treat diseases.
Also, the collaboration will enable Illumina to improve its foothold in the global IVD market.
Significance of the Collaboration
Per the terms of the partnership, Illumina will develop customized software to support the use of the kits on NextSeq instruments. Also, the company will provide regulatory and related support related to its components as well as the software. It will exclusively license the software to Adaptive Biotechnologies. These test kits will enable hospitals and healthcare providers to use Adaptive Biotechnologies’ clonoSEQ and immunoSEQ Dx assays in their respective laboratories across the United States.
Through this collaboration, Illumina aims to reach out to more people to ensure better access to healthcare. Also, it plans to make clonoSEQ more accessible to patients and include the healthcare providers into the growing genomics ecosystem. The partnership will facilitate Illumina to expand access to genomic-based testing and improve patient outcomes.
A Peek Into Illumina’s IVD Portfolio
Illumina’s next-generation sequencing (NGS) technology offers broader view of the human genome. This helps clinicians to determine and apply relevant genomic information to human health. The company is focused on improving health by tapping the huge potential of the human genome.
Illumina is currently aiming to expand the clinical applications of its NGS platform through products like the MiSeqDx System and the TruSeq Custom Amplicon Kit Dx.
Recent Developments
The company announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to noninvasive prenatal testing (NIPT) in June 2019. It is an automated comprehensive solution that enables laboratories to look for a broader array of chromosomal and sub-chromosomal conditions associated with birth defects as well as adverse pregnancy outcomes than the standard NIPT menu.
Industry Prospects
Per a report by Research And Markets, the global IVD market value is anticipated to reach $92.54 billion at a CAGR of 6.6%, for the period spanning from 2018 to 2023. The key factors driving the market is the increasing numbers of diabetic patients, rising incidents of chronic ailments, surging healthcare expenditure and rising elderly population.
Given the current trend, Illumina signed this distribution deal just at the right time.
Price Performance
The company’s shares have plunged 18.3% in the past year compared with the industry’s decline of 27.5%. However, the S&P 500 index inched up 0.9% during the same period.
Zacks Rank & Key Picks
Currently, Illumina carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Capricor Therapeutics, Inc (CAPR - Free Report) and GW Pharmaceuticals PLC .
Capricor, sporting a Zacks Rank #1 (Strong Buy), has a projected third-quarter 2019 earnings growth rate of 28.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals estimates third-quarter earnings growth rate to be 72.8%. It currently flaunts a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>